Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07614321 · ClinicalTrials.gov registry record · Phase 4
Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis
A Phase 4 study, sponsored by Atlantic Health System.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 60
- Enrollment target
NCT07614321: Recruiting Phase 4 study, sponsored by Atlantic Health System.
NCT07614321 is a Phase 4 study that is actively recruiting participants, run by Atlantic Health System. The registered enrollment target is 60 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07614321, a Phase 4 study, is actively recruiting participants, sponsored by Atlantic Health System.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 60 participants
- Enrollment target
Study Summary
The goal of this clinical trial is to learn if silodosin works to treat lower urinary tract symptoms (LUTS) in female patients with multiple sclerosis (MS). It will also learn about the effect of the drug on voiding parameters. The main questions it aims to answer are: Does silodosin improve lower urinary tract symptoms based on questionnaires? Does silodosin change Uroflowmetry parameters in female patients with MS? Researchers will compare silodosin to a placebo (a look-alike substance that contains no drug) to see if silodosin works to treat LUTS in female patients with MS. Participants will: Take silodosin or a placebo every day for 8 weeks Visit the clinic before initiating the medication and after 8 weeks of taking the medication for questionnaires and tests
Primary Outcome
Score 0-35, higher score indicating worse symptoms therefore higher change from baseline indicating better improvement
Interventions
- DRUG Placebo
- DRUG Silodosin 8 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2026-04 |
| Est. Completion | 2028-04 |
| Phase | Phase 4 |
What NCT07614321 shows while recruiting
NCT07614321 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07614321 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07614321 about?
NCT07614321 is a clinical study titled "Silodosin for Urinary Symptoms in Female Patients With Multiple Sclerosis". The goal of this clinical trial is to learn if silodosin works to treat lower urinary tract symptoms (LUTS) in female patients with multiple sclerosis (MS). It will also learn about the effect of the drug on voiding parameters. The main questions it aims to answer are: Does silodosin improve lower ...
What is the current status of trial NCT07614321?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 60 participants. The study started on 2026-04. Estimated completion is 2028-04.
What interventions are being tested in trial NCT07614321?
The interventions under investigation include: Placebo (DRUG), Silodosin 8 mg (DRUG).
Who is sponsoring clinical trial NCT07614321?
This trial is sponsored by Atlantic Health System, which has 43 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07614321's enrollment target sits among peer trials
60 1125th of 2000 higher than 799 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00576069 · 60 participants
Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma
- NCT01297400 · 60 participants · Phase 2
Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns
- NCT01734122 · 60 participants
Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor
- NCT01804634 · 60 participants · Phase 2
Reduced Intensity Haploidentical BMT for High Risk Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia